Evaxion adds EVX-05 off-the-shelf glioblastoma vaccine program to R&D pipeline
EVAX•EVX-05 added to R&D pipeline
Evaxion added EVX-05, an off-the-shelf therapeutic vaccine program for glioblastoma, designed using its AI-Immunology platform.
The candidate targets conserved endogenous retrovirus-derived antigens identified from patient tumor samples, aiming to broaden applicability across glioblastoma patients.
Pipeline refocus and cash runway
Pipeline refocus included discontinuation of EVX-03; EVX-05 costs remain within existing budgets, keeping cash runway into 2H 2027.
Program advances toward lead-candidate optimization
The program moved into lead-candidate optimization, advancing toward initial clinical testing expected to be run with Duke University School of Medicine.
